title: CYP2C9 variant modifies blood pressure-lowering response to losartan in Type 1 diabetic patients with nephropathy.
authors.forename: M
authors.initials: M
authors.lastname: Lajer
authors.forename: L
authors.initials: L
authors.lastname: Tarnow
authors.forename: S
authors.initials: S
authors.lastname: Andersen
authors.forename: H-H
authors.initials: HH
authors.lastname: Parving
mesh_terms: D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001189:Aryl Hydrocarbon Hydroxylases / Q000378:metabolism*; D065729:Cytochrome P-450 CYP2C9; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D003928:Diabetic Nephropathies / Q000188:drug therapy*; D005260:Female; D006801:Humans; D019808:Losartan / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D000959:Antihypertensive Agents; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases; D019808:Losartan